Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market

pages

English

Documents

2014

Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris

pages

English

Ebook

2014

Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Publié par

frost-sullivan

Publié le

29 janvier 2014

Nombre de lectures

Langue

English

Frost & Sullivan: Strong Pipeline ofFrost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market PR Newswire LONDON, Jan. 29, 2014 - The market is expected to soar from $1.

Voir

Publié par

frost-sullivan

Publié le

29 janvier 2014

Nombre de lectures

Langue

English

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market

PR Newswire

LONDON, Jan. 29, 2014

- The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019

The imminent entry of several companies, including big pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth. Already, Indian groups such as Dr. Reddy's Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market. Although these companies have not yet penetrated the European market due to the stringent regulatory pathway, new product launches are expected in the mid-term.

Voir